MTEX on Nasdaq

Mannatech

Logo: Mannatech, Public domain, via Wikimedia Commons4

Multinational multi-level marketing company

Mannatech Inc. is a publicly traded, multinational multi-level marketing firm that sells dietary supplements and personal care products. It was founded in November 1993 by Samuel Caster, and is headquartered in Flower Mound, Texas. The company's stock is traded on the NASDAQ exchange under the symbol MTEX.3 Wikipedia text CC BY-SA 4.0

Price unavailable

Last updated Oct 21, 2026.

Overview

1994Founded1

Compare with Niagen Bioscience, Inc., Natural Alternatives International or Cronos Group Inc, or pick any stock.

  • TickerMTEX on Nasdaq1
  • Industryfood industry1
  • HeadquartersFlower Mound1
  • Websitewww.mannatech.com
  • Incorporated inTX5
  • Business address1410 Lakeside Parkway, Suite 200, Flower Mound, Tx 750285
  • Filer categoryNon-accelerated filer, Smaller reporting company5
Mannatech HQ
Photo: Prhartcom, CC BY-SA 4.0, via Wikimedia Commons7

Mannatech Inc. is a publicly traded, multinational multi-level marketing firm that sells dietary supplements and personal care products. It was founded in November 1993 by Samuel Caster, and is headquartered in Flower Mound, Texas. The company's stock is traded on the NASDAQ exchange under the symbol MTEX. As of 2017, Mannatech employed 252 people and sold its products through some 220,000 independent sales associates.3

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2025

74.9%Gross margin8
-0.4%Operating margin8
-14.1%Net margin8
-8.3%Revenue growth, 20258
-$4.3MFree cash flow8

What sells

Revenue by product, business segment and region, as the company reports it to the SEC.

Products and services

Product brought in 98% of the revenue Mannatech broke down this way in fiscal 2025.

  1. Product$106.0M898%down 9% from 2024
  2. Product and Service, Other$1.6M81%up 7% from 2024
  3. Associate Service Fees$400.0K80%down 20% from 2024
Products and services by year
Products and services20242025
Product$115.9M$106.0M
Product and Service, Other$1.5M$1.6M
Associate Service Fees$500.0K$400.0K

Where the money goes

Where each dollar of revenue went, fiscal 2025

  • Cost of revenue25¢$27.1M
  • Research and development1¢$800.0K
  • Selling, general and admin37¢$39.7M
  • Other costs26¢$28.2M
  • Income tax11¢$12.3M

Out of $108.0M in revenue.8 The company lost money this year.

Financial statements

Revenue9101112138$108.0M in 2025−32% since 2019
0$50.0M$100.0M$150.0M$200.0M2019: $157.7M$157.7M20192020: $151.4M$151.4M2020−4%2021: $159.8M$159.8M2021+6%2022: $137.2M$137.2M2022−14%2023: $132.0M$132.0M2023−4%2024: $117.9M$117.9M2024−11%2025: $108.0M$108.0M2025−8%
Gross profit9101112138$81.0M in 2025−36% since 2019
0$50.0M$100.0M$150.0M2019: $126.2M$126.2M20192020: $115.9M$115.9M2020−8%2021: $125.6M$125.6M2021+8%2022: $104.1M$104.1M2022−17%2023: $102.9M$102.9M2023−1%2024: $91.5M$91.5M2024−11%2025: $81.0M$81.0M2025−11%
Operating income9101112138-$426.0K in 2025
-$5.0M0$5.0M$10.0M2019: $6.4M$6.4M20192020: $4.5M$4.5M2020−30%2021: $9.0M$9.0M2021+101%2022: -$405.0K-$405.0K20222023: -$964.0K-$964.0K2023+138%2024: $1.4M$1.4M20242025: -$426.0K-$426.0K2025
Net income9101112138-$15.2M in 2025
-$20.0M-$10.0M0$10.0M2019: $3.3M$3.3M20192020: $6.3M$6.3M2020+90%2021: $9.8M$9.8M2021+57%2022: -$4.5M-$4.5M20222023: -$2.2M-$2.2M2023−50%2024: $2.5M$2.5M20242025: -$15.2M-$15.2M2025

Every line of the income statement as filed: the last 2 fiscal years, latest first.8

Period ending2025-12-312024-12-31
Net sales$108.0M$117.9M
Cost of sales$27.1M$26.4M
Gross profit$81.0M$91.5M
Commissions and incentives$41.7M$48.3M
Selling and administrative expenses$39.7M$41.7M
Total operating expenses$81.4M$90.0M
(Loss) income from operations-$426.0K$1.4M
Interest expense, net-$406.0K-$279.0K
Other Nonoperating Income (Expense)-$2.1M$2.6M
(Loss) income before income taxes-$2.9M$3.7M
Income tax expense-$12.3M-$1.2M
Net (loss) income-$15.2M$2.5M
Basic (in dollars per share)-$8.00$1.32
Diluted (in dollars per share)-$8.00$1.32
Basic (in shares)1.9M shares1.9M shares
Diluted (in shares)1.9M shares1.9M shares

Compare Mannatech with another company

Corporate structure

Mannatech sits at the top of its group. 1 entity, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.

Major holders of Mannatech

  • Terry Lacore Filed SCHEDULE 13G/A on Mannatech, latest Aug 19, 2026 (3 filings since Jan 24, 2025)
  • Robert Toth Filed SCHEDULE 13D on Mannatech, latest Apr 24, 2026
  • Marlin Ray Robbins Filed SC 13G on Mannatech, latest Nov 1, 2024
  • Sudbury Capital Fund, LP Filed SC 13G/A on Mannatech, latest Jan 13, 2023 (2 filings since Jan 4, 2022)
  • Michael Challen Filed SC 13G/A on Mannatech, latest Feb 8, 2022
  • Mannatech Flower Mound

Built from major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What Mannatech reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

ItemLatestA year beforeChange
Construction in progress$151.0K13 Dec 31, 2024$194.0K13 Dec 31, 2023−22.2%
Property and equipment, before depreciation$54.9M8 Dec 31, 2025$55.6M8 Dec 31, 2024−1.2%
Accumulated depreciation$52.7M8 Dec 31, 2025$52.9M8 Dec 31, 2024−0.4%
Property and equipment, net$2.2M8 Dec 31, 2025$2.7M8 Dec 31, 2024−17.7%
Finance-lease assets$684.0K8 Dec 31, 2025$961.0K8 Dec 31, 2024−28.8%
Operating-lease assets (leased space)$3.3M8 Dec 31, 2025$2.1M8 Dec 31, 2024+57.2%

Investments

ItemLatestA year beforeChange
Cash and cash equivalents$6.2M8 Dec 31, 2025$11.4M8 Dec 31, 2024−45.7%

Intangibles and goodwill

ItemLatestA year beforeChange
Indefinite-lived intangibles (excluding goodwill)$200.0K13 Dec 31, 2024$200.0K13 Dec 31, 20230%

Inventory

ItemLatestA year beforeChange
Inventory, total$10.1M8 Dec 31, 2025$10.4M8 Dec 31, 2024−2.7%
Raw materials$2.1M8 Dec 31, 2025$4.4M8 Dec 31, 2024−52.4%
Finished goods$8.0M8 Dec 31, 2025$6.0M8 Dec 31, 2024+34.2%

Properties, in its own words

We lease property at several locations for our headquarters and distribution facilities, including:

Location · Area · Expiration date

The rest of Item 2

Flower Mound, Texas (corporate headquarters) · 52,992 sq. feet · June 2028

St. Leonards, Australia (Australian headquarters) · 1,668 sq. feet · June 2026

Minago-Ku Tokyo, Japan (Shinagawa Grand Central Tower) · 3,497 sq. feet · April 2027

Yeongnam Tower, Sincheon-dong, (Daegu Center) · 3,557 sq. feet · June 2026

Gangnam-gu, Seoul, Korea (Republic of Korea headquarters) · 10,596 sq. feet · September 2028

Gangnam-gu Seoul, Korea (Seoul training center) · 18,441 sq. feet · September 2028

Haewoondae-gu, Busan, Korea (Pusan training center) · 6,800 sq. feet · March 2027

Incheon, South Korea (Incheon training center) · 7,754 sq. feet · April 2026

Taiwan Bldg 13F Taipei City (Shu-Yeng CHEN) · 93 sq. feet · August 2026

Tsuen Wan, New Territories, Hong Kong (new office) · 2,032 sq. feet · April 2028

Hengqin, Zhuhai, China (office) · 930 sq. feet · September 2026

Tianhe, Guangzhou, China (office) · 110 sq. feet · July 2026

Guangzhou Experience Center · 3,767 sq. feet · February 2028

Richmond, British Columbia, Canada (Canada training center) · 1,963 sq. feet · September 2026

Bedfordview, South Africa (office) · 4,123 sq. feet · N/A (1)

Guadalajara, Mexico (office) · 5,382 sq. feet · July 2028

Mexico City, 1st flr Mexico (customer service center) · 1,324 sq. feet · August 2026

Mexico City, 3rd flr Mexico (office) · 1,324 sq. feet · August 2026

Amsterdam, Netherlands (shared office space) · 50 sq. feet · August 2026

Bangkok, Thailand (CW Tower) (Unit 404) · 397 sq. feet · May 2026

(1) Renewable monthly.

To maximize our operating strategy and minimize costs, we contract with third-party distribution and fulfillment facilities in our three regions: (i) the Americas, (ii) EMEA and (iii) Asia/Pacific. By entering into these third-party distribution facility agreements, our offices maintain flexible operating capacity, minimize shipping costs, and are able to process an order within 24-hours after order placement and receipt of payment.

Item 2 of the 10-K filed Apr 15, 2026.16

The story

Founded by Samuel Caster in 1994.1

Mannatech was founded by Samuel Caster in 1993, as Congress prepared to pass the Dietary Supplement Health and Education Act of 1994, which made feasible the profitable marketing of a wider spectrum of dietary supplements. The company has had a Christian orientation since its founding; the name was intended to evoke manna, and it recruited people to sell its products through its multi-level marketing structure in church congregations. Prior to founding Mannatech, Caster had founded and run Eagle Shield, an insulation manufacturer, and Electracat, a pest control device; both were categorized as a hoax by the Texas Attorney General's office.

Mannatech was founded to sell dietary supplements and personal care products. Before developing its own products, the company sold Manapol, an aloe vera extract made by another company. Its most widely known product has been Ambrotose, a dietary supplement made from sugars derived from plants.

From 1993 to 2009, Rafael Cruz, father of presidential candidate Ted Cruz, was a top salesman for Mannatech.

Mannatech had its initial public offering (IPO) on February 16, 1999, at $8 a share. The stock price settled a few weeks later at a price of $15.13 a share and a market capitalization of $366 million. The IPO raised $12 million in funds to be used for expansion into Australia and the U.K.

False claims and lawsuits

The company came to be known for unproven claims that its products could be used to treat many diseases and conditions, including cancer, diabetes, autism and AIDS. There is no evidence that any of these claims were or are true.

In May 2005 an article was published in Barron's questioning the company's business practices. In September 2005, a class-action lawsuit was filed against Mannatech for alleged violations of the Securities Exchange Act; it was prompted by the Barron's article.

In 2006, Mannatech distributor Vivienne Balonwu, a U.K. general practitioner, was found by the U.K. General Medical Council panel to have "abused her power as a doctor" after it was determined that she had illegally promoted and sold the company's products to people as a treatment for medical conditions such as chronic obstructive pulmonary disease and stroke-related complications. Following patient complaints about her marketing of the products in 2006, Balonwu was dismissed by her employer, Harmoni, a medical services company, and the GMC panel imposed a 15-month penalty period during which she was "to avoid private or short term locum work" and "to complete a supervised personal development plan to tackle shortcomings in her practice".

Also in 2006, Mannatech was named #5 on Forbes’ list of America's 200 Best Small Companies. At the same time, the company came under investigation by the Texas Attorney General in October 2006 for alleged violations of that state's Deceptive Trade Practices Act. In July 2006, Texas Attorney General Greg Abbott formally charged Mannatech, MannaRelief, Sam Caster, and Reginald McDaniel, the company's medical director, with operating an illegal marketing scheme in violation of state law.

Read the full text

A 20/20 undercover investigation that aired June 1, 2007 on ABC Television showed Mannatech's sales associates teaching sales recruits how to target Mannatech products to people with specific illnesses in a manner that purportedly does not violate U.S. federal law, including U.S. Food and Drug Administration regulations, by avoiding direct claims that the products cure any particular diseases.

In August 2007, Caster resigned as CEO of Mannatech. In October 2007, it was reported that the company had fired Grant Thornton LLP as its auditor after the accounting firm demanded that Mannatech remove Caster from all responsibilities to be replaced by Wayne Badovinus as the new chief executive. Several corporate initiatives were undertaken, but after 17 months on the job Badovinus resigned in December 2009. Another member of the board resigned shortly after. Mannatech's Chief Science Officer Robert Sinnott and Mannatech's chief financial officer Steve Fenstermacher were named Co-CEOs. Fenstermacher later resigned.

Publicity over the company's lawsuits began to damage the balance sheets and stock performance. After profits of $32 million in 2006 and $6.6 million in 2007, Mannatech reported a $12.6 million loss in 2008 and a $17.3 million loss in 2009.

Mannatech settled the civil complaint with the State of Texas in February 2009; Mannatech did not admit wrongdoing but agreed to pay $4 million in restitution to clients who purchased products and $2 million to the state to cover its costs in the case. In addition, Sam Caster agreed to pay a $1 million civil penalty and steer clear of any type of leadership position or employment relationship with Mannatech for five years.

In March 2008, Mannatech settled the class-action lawsuit by agreeing to pay $11.25 million to the plaintiff class. As part of the settlement, Mannatech admitted no wrongdoing.

2010 losses were $10.6 million. As the company's market capitalizations continued to fall, S&P Indices dropped it from the S&P 600 Index, stating "They are no longer representative of the small cap market space." Recruiting efforts continued dropping in 2011, widening company losses to $20.6 million. For 2012, the company's net loss narrowed to around $1 million from the about $21 million loss the year before. In 2013, it had around $3 million in net income, and in 2014, it reported profits of $6.5 million and total revenue of $190.1 million.

In November 2017, Mannatech received an FDA warning letter for illegally marketing several of its supplement products as medicinal agents and for selling adulterated and misbranded products in violation of Title 21 of the Code of Federal Regulations and Good Manufacturing Practice regulations for dietary supplements. In December 2017, Mannatech reached an agreement with the Town Council of Flower Mound, Texas, to relocate its headquarters to an existing facility in the city.

Ben Carson

Starting in 2004, neurosurgeon and conservative politician Ben Carson made videos and spoke at company events promoting Mannatech and its products. In 2004, in a speech at a Mannatech event, he credited the company's products with the disappearance of his cancer symptoms.

Carson's image still appeared on the Mannatech's website in 2014, and in the same year he praised their "glyconutrient" supplements in a PBS special (The Missing Link – The Science of Brain Health), sponsored by a group of Mannatech distributors, that was subsequently featured on the site. During the CNBC GOP debate on October 28, 2015, Carson was asked about his relationship with Mannatech and denied any involvement with the company. Politifact rated Carson's denial of any involvement as "false". In November 2015, Mannatech said on its website that, for compliance with Federal campaign finance regulations, the company had removed all references to Carson before he announced his bid for the presidency.

From Wikipedia’s article on Mannatech, shared under CC BY-SA 4.0.6

Leadership

Who has led Mannatech, and when. Pick a name to see everywhere that person has worked.

Board members and other officers (30)

Timeline

  1. Oct 14, 20268-K Other events64
  2. Sep 1, 20268-K Executive or director change65
  3. Aug 12, 20268-K Results of operations66
  4. Jun 8, 20268-K Executive or director change67
  5. Jun 3, 20268-K Shareholder vote68
  6. May 14, 20268-K Results of operations69
  7. Apr 24, 20268-K Listing notice or transfer70
  8. Apr 15, 20268-K Results of operations71
  9. Apr 2, 20268-K Other events72
  10. Mar 24, 20268-K Executive or director change73
  11. Nov 12, 20258-K Results of operations74
  12. Sep 12, 20258-K Entered a material agreement75
  13. Jun 5, 2025New chief executive Landen Granvel Fredrick becomes CEO17
  14. Aug 28, 2015New chief executive Alfredo Bala becomes CEO18
  15. Dec 23, 2009New chief executive Stephen D. Fenstermacher becomes CEO19
  16. Jun 23, 2008New chief executive Wayne Badovinus becomes CEO20
  17. Sep 7, 2007New chief executive Terry L. Persinger becomes CEO21
  18. 1994Founded Founded1

Calendar

Coming up

  1. Nov 11, 2026Reports results for the quarter ending Sep/202676

When it reported results

  1. Aug 12, 2026Reported quarterly or annual results66
  2. May 14, 2026Reported quarterly or annual results69
  3. Apr 15, 2026Reported quarterly or annual results71
  4. Nov 12, 2025Reported quarterly or annual results74
  5. Nov 12, 2024Reported quarterly or annual results77
  6. Aug 13, 2024Reported quarterly or annual results78
  7. May 14, 2024Reported quarterly or annual results79
  8. Mar 28, 2024Reported quarterly or annual results80

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar

Filings

172 filings to the SEC since October 2021: 5 annual reports, 15 quarterly reports, 54 major events, 71 insider forms, 8 large holders, 19 other. The latest 20:

  1. Oct 14, 20268-K EDGAR
  2. Sep 1, 20268-K EDGAR
  3. Aug 19, 2026SCHEDULE 13G/A EDGAR
  4. Aug 19, 2026SCHEDULE 13G/A EDGAR
  5. Aug 12, 20268-K EDGAR
  6. Aug 12, 202610-Q EDGAR
  7. Jun 18, 20264 EDGAR
  8. Jun 18, 20263 EDGAR
  9. Jun 8, 20268-K EDGAR
  10. Jun 5, 20264 EDGAR
  11. Jun 5, 20264 EDGAR
  12. Jun 3, 20268-K EDGAR
  13. May 21, 20264 EDGAR
  14. May 20, 20264 EDGAR
  15. May 20, 20264 EDGAR
  16. May 14, 20268-K EDGAR
  17. May 14, 202610-Q EDGAR
  18. Apr 24, 20268-K EDGAR
  19. Apr 24, 2026SCHEDULE 13D EDGAR
  20. Apr 21, 2026DEFA14A EDGAR

The 172 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

13 open-market trades by officers, directors and large owners since October 2021: 4 buys and 9 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
May 20, 2026JOBE LARRY ADirectorBuy2,803$4.12$11.5KForm 4
May 19, 2026JOBE LARRY ADirectorBuy5,000$4.20$21.0KForm 4
May 19, 2026Robbins Kevin AndrewDirectorBuy7,100$4.17$29.6KForm 4
Sep 9, 2024JOBE LARRY ADirectorSale16,288$7.75$126.2KForm 4
Sep 9, 2024Rameson TylerDirectorBuy16,288$7.75$126.2KForm 4
May 22, 2024JOBE LARRY ADirectorSale1,012$7.60$7.7KForm 4
Aug 30, 2023BALA ALFREDOCEO and PresidentSale1,000$12.40$12.4KForm 4
Aug 18, 2023JOBE LARRY ADirectorSale1,217$12.82$15.6KForm 4
Jun 30, 2023BALA ALFREDOCEO and PresidentSale115$12.62$1.5KForm 4
Jun 29, 2023BALA ALFREDOCEO and PresidentSale154$12.89$2.0KForm 4
Dec 21, 2022BALA ALFREDOCEO and PresidentSale3,500$19.69$68.9KForm 4
Dec 8, 2022Robbins Kevin AndrewDirectorSale1,500$22.00$33.0KForm 4
Mar 28, 2022Robbins Kevin AndrewDirectorSale1,100$36.57$40.2KForm 4

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

  • Terry LacoreSCHEDULE 13G/A, 3 filings Jan 24, 2025 to Aug 19, 202681
  • Robert TothSCHEDULE 13D, 1 filing Apr 24, 202682
  • Marlin Ray RobbinsSC 13G, 1 filing Nov 1, 202483
  • Sudbury Capital Fund, LPSC 13G/A, 2 filings Jan 4, 2022 to Jan 13, 202384
  • Michael ChallenSC 13G/A, 1 filing Feb 8, 202285

Executive pay

What the company paid its top executives, from the summary compensation table in its proxy statement. Total pay includes salary, bonus, stock and option awards and other pay, as the company valued them.

YearExecutiveAgeSalaryTotal pay
2025Landen Fredrick53$350.6K$368.8K86
2025James Clavijo60$275.0K$289.7K86
2024President and Chief Executive Officer$321.5K$330.9K86
2024Chief Financial Officer$147.2K$157.4K86

Held by these funds

The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026. Change is in shares since the quarter before.

FundSharesValueShare of the fundChange
BlackRock, Inc.52,163$271.8K0.0%No change
Vanguard Capital Management LLC41,528$216.4K0.0%−8,089
Renaissance Technologies LLC30,078$156.7K0.0%−800
IFG Advisory, LLC19,090$99.5K0.0%New
Vanguard Fiduciary Trust Co2,679$14.0K0.0%No change
Tower Research Capital LLC (TRC)727$3.8K0.0%+255
Royal Bank Of Canada316$2.0K0.0%+236
Vanguard Global Advisers, LLC250$1.3K0.0%No change
Wells Fargo & Company/mn201$1.0K0.0%+200
UBS Group AG48$2500.0%−437
National Bank Of Canada /fi/30$1500.0%No change
Arax Advisory Partners12$630.0%No change
Acadian Asset Management LLC4,690$240.0%−3,051
Morgan Stanley2$150.0%No change
Citigroup Inc1$50.0%New
SBI Securities Co., Ltd.1$50.0%No change

13F reports cover disclosed long positions in U.S. stocks only.

SEC filer profile

How Mannatech is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARMANNATECH INC2
  • CIK0001056358
  • Employer ID (EIN)75-250890016
  • Filer statusNon-accelerated filer not an emerging growth company; a smaller reporting company; not a shell company16
  • Incorporated inTexas16
  • Fiscal year endsDecember 312
  • Industry code (SIC)2833 Medicinal Chemicals & Botanical Products2
  • SEC reviewing officeOffice of Life Sciences, Division of Corporation Finance2
  • Business address1410 Lakeside Parkway, Suite 200, Flower Mound, TX 750282
  • Phone97247174002
  • Shares outstanding1,929,670 as of Aug 5, 202615
  • Public float$9.9M as of Jun 30, 202516
  • AuditorBDO USA, P.C., Dallas, Texas, USA PCAOB ID 24316
  • On EDGAR sinceApr 10, 19982
  • Filings1,184 in all: 4 (500), 8-K (297), 10-Q (83), 3 (43), 4/A (31), DEF 14A (28), 10-K (27), SC 13G/A (21)2
    All 44 form types

    DEFA14A (18), SC 13G (15), S-1/A (10), S-8 (10), SC TO-I/A (10), CORRESP (9), UPLOAD (9), CT ORDER (7), 144 (6), ARS (6), 3/A (4), 8-K/A (4), SC 13D (4), SC TO-C (4), SC TO-I (4), 10-K/A (3), S-1 (3), SC 13D/A (3), 10-Q/A (2), 8-A12G (2), DEFR14A (2), NT 10-K (2), RW (2), S-3 (2), SCHEDULE 13G/A (2), 10-K405 (1), 15-12G (1), 5 (1), DEF 14C (1), EFFECT (1), NT 10-K/A (1), POS AM (1), PRE 14A (1), PRE 14C (1), SCHEDULE 13D (1), SCHEDULE 13G (1)

  • Latest filingsAnnual report (10-K) Apr 15, 2026
    Quarterly report (10-Q) Aug 12, 2026
    Proxy statement (DEF 14A) Apr 21, 2026
    Latest 8-K (8-K) Oct 14, 2026

Securities registered for trading

ClassSymbolExchange
Common Stock, par value $0.0001 per shareMTEXNasdaq

From the cover page of the 10-K filed Apr 15, 2026 (Section 12(b) of the Exchange Act).16

Risk factors and legal proceedings

The risks Mannatech names in Item 1A of its 10-K filed Apr 15, 2026: 39 risks under these headings, as written.16

  • If we are unable to attract and retain independent associates, our business may suffer.
  • The loss of key high-level independent associate leaders could negatively impact our associate growth and our revenue.
  • Changes to our associate compensation arrangements could be viewed negatively by some independent associates, could cause failure to achieve desired long-term results and have a negative impact on revenue.
  • An increase in the amount of commissions and incentives paid to independent associates could adversely affect our earnings.
  • The loss of key management personnel could adversely affect our business, financial condition, results of operations or independent associate relations.
  • If we are unable to protect the proprietary rights of our products, our business could suffer.
  • Our inability to develop and introduce new products that gain independent associate, preferred customer, and market acceptance could harm our business.
  • Our failure to appropriately respond to changing consumer preferences and demand for new products or product enhancements could significantly harm our relationship with independent associates and preferred customers, our product sales, as well as our financial condition and operating results.
  • If our outside suppliers and manufacturers fail to supply products in sufficient quantities and in a timely fashion or fail to comply with our product safety and quality standards or applicable law, our business could suffer.
  • The loss of suppliers, shortages of raw materials or our failure to satisfy minimum purchase requirements could have an adverse effect on our business, financial condition, or results of operations.
  • If we are exposed to product liability claims, we may be liable for damages and expenses, which could affect our overall financial condition, results of operations and cash flows.
  • Concentration Risk
The other 28 risks
  • If we incur substantial liability from litigation, complaints, or enforcement actions or incur liabilities or penalties resulting from misconduct by our independent associates, our financial condition could suffer and could have a negative impact on our profitability and growth prospects.
  • The global nutrition and skin care industries are intensely competitive and there is risk associated with competition from larger, more established companies who have greater financial resources.
  • A downturn in the economy, could affect consumer purchases of discretionary items such as the health and wellness products that we offer, which could have an adverse effect on our business, financial condition, profitability, and cash flows.
  • Adverse or negative publicity could cause our business to suffer.
  • If our information technology system fails or if the implementation of new information technology systems is not executed efficiently and effectively, our business, financial position, and operating results could be adversely affected.
  • We use artificial intelligence in our business, and challenges with properly managing its use could result in reputational harm, competitive harm, and legal liability, and adversely affect our results of operations.
  • Interruption or failure of our information technology and communications systems could impair the delivery of our service and harm our business.
  • We rely upon our existing cash balances and cash flow from operations to fund our business and meet our contractual obligations. In the event that we do not generate adequate cash flow from operations, we will need to raise money through a debt or equity financing, if available, or curtail operations.
  • We have outstanding debt with our directors. Such indebtedness could adversely affect our cash flow and our ability to pursue desirable business opportunities.
  • We are subject to liquidity risk, which could adversely affect our financial condition and results of operations.
  • Our financial statements contain a statement regarding a substantial doubt about the Company’s ability to continue as a going concern.
  • If our international markets are not successful, our business could suffer.
  • Currency exchange rate fluctuations could reduce our overall profits.
  • If government regulations regarding network marketing change or are interpreted or enforced in a manner adverse to our business, we may be subject to new enforcement actions and material limitations regarding our overall business model.
  • Independent associates could fail to comply with our associate policies and procedures or make improper product, compensation, marketing or advertising claims that violate laws or regulations, which could result in claims against us that could harm our financial condition and operating results.
  • We may be held responsible for certain taxes or assessments relating to the activities of our independent associates, which could harm our financial condition and operating results.
  • Challenges by private parties to the form of our network marketing system could harm our business.
  • If our network marketing activities do not comply with government regulations, our business could suffer.
  • The Company may, directly or indirectly, be affected by government laws and regulations related to climate change.
  • If we violate governmental regulations or fail to obtain necessary regulatory approvals, our operations could be adversely affected.
  • Increased regulatory scrutiny of nutritional supplements as well as new regulations that are being adopted in some of our markets with respect to nutritional supplements could result in more restrictive regulations and harm our results if our supplements or advertising activities are found to violate existing or new regulations or if we are not able to effect necessary changes to our products in a timely and efficient manner to respond to new regulations.
  • Taxation and transfer pricing affect our operations and we could be subjected to additional taxes, duties, interest, and penalties in material amounts, which could harm our business.
  • Our stock price is volatile and may fluctuate significantly.
  • Certain shareholders, directors, and officers own a significant amount of our stock, which could allow them to influence corporate transactions and other matters.
  • We have implemented anti-takeover provisions that may help discourage a change of control.
  • Our failure to comply with The Nasdaq Capital Market continued listing standards may adversely affect the price and liquidity of our shares of common stock as well as our ability to raise capital in the future.
  • We are not required to pay dividends, and our Board of Directors may decide not to declare dividends in the future.
  • The reduced disclosure requirements applicable to us as a "smaller reporting company" may make our common stock less attractive to investors.

Legal proceedings

See Note 14 to our Consolidated Financial Statement, Litigation, which is incorporated herein by reference.

The opening of Item 3, Legal Proceedings.16

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35
  36. 36
  37. 37
  38. 38
  39. 39
  40. 40
  41. 41
  42. 42
  43. 43
  44. 44
  45. 45
  46. 46
  47. 47
  48. 48
  49. 49
  50. 50
  51. 51
  52. 52
  53. 53
  54. 54
  55. 55
  56. 56
  57. 57
  58. 58
  59. 59
  60. 60
  61. 61
  62. 62
  63. 63
  64. 64
    SEC EDGAROther events
  65. 65
  66. 66
  67. 67
  68. 68
  69. 69
  70. 70
  71. 71
  72. 72
    SEC EDGAROther events
  73. 73
  74. 74
  75. 75
  76. 76
  77. 77
  78. 78
  79. 79
  80. 80
  81. 81
  82. 82
  83. 83
  84. 84
  85. 85
  86. 86